Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.63 |
| ▸ | BRD2 | P25440 | 2/20 | 0.63 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.63 |
| ▸ | TPH2 | Q8IWU9 | 11/20 | 0.63 |
| ▸ | TPH1 | P17752 | 10/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21389536 | 0.86 | BRD4 (0.57) | BRD4BRD2BRD3TPH2TPH1 | |
| SCHEMBL19090210 | 0.84 | TPH2 (0.57) | BRD4BRD2BRD3TPH2TPH1 | |
| SCHEMBL21389544 | 0.84 | BRD4 (0.63) | BRD4BRD2BRD3TPH2TPH1 | |
| SCHEMBL21389479 | 0.81 | BRD4 (0.58) | BRD4BRD2BRD3TPH2TPH1 | |
| SCHEMBL21389573 | 0.81 | BRD4 (0.52) | BRD4BRD2BRD3TPH2TPH1 | |
| SCHEMBL21389564 | 0.81 | BRD4 (0.52) | BRD4BRD2BRD3TPH2TPH1 | |
| SCHEMBL23730984 | 0.80 | BRD4 (0.51) | BRD4BRD2BRD3TPH2TPH1 | |
| SCHEMBL21389551 | 0.80 | ALDH1A1 (0.58) | BRD4BRD2BRD3TPH2TPH1 | |
| SCHEMBL21389579 | 0.78 | MEN1 (0.66) | BRD4BRD2BRD3TPH2TPH1 | |
| SCHEMBL21389558 | 0.78 | BRD4 (0.73) | BRD4BRD2BRD3TPH2TPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-01-18 | — | — | US | disclosed |
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | BET1, BRD4, BRD3 | BRD4 2/4885BRD2 6/4885BRD3 3/4885 |
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | BET1, BRD4, BRD3 | BRD4 2/4885BRD2 6/4885BRD3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.